{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:09:07Z","timestamp":1788952147674,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Introduction<\/jats:title>\n The associations between gut microbiota and disease progression, as well as the prognostic implications of gut microbiota, remain unclear in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs). This study aimed to delineate gut microbiome differences among ICI-treated patients with intermediate-to-advanced HCC and assess their correlations with clinical outcomes via meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched 4 databases (PubMed, Embase, Web of Science, and the Cochrane Library) and collected related articles published before May 31, 2026. We calculated standard mean differences (SMDs) and 95% confidence intervals (CIs) using a random-effects model. Summarized hazard ratios (HRs) with 95% CIs were used to assess gut microbiome associations with overall survival (OS) and progression-free survival (PFS). Subgroup, sensitivity, and publication bias analyses were further conducted, with all statistical analyses performed using RevMan and R.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 13 eligible papers were included. (1) The meta-analysis of Alpha diversity indices between R and NR was no significant difference, but over 68% of the studies reported significant differences in beta diversity. (2) At the phylum level,\n Actinobacteriota<\/jats:italic>\n were significantly enriched in the R group. At the genus level, depleted\n Bacteroides<\/jats:italic>\n exhibited distinct relative abundance in the NR group. (3) Protective taxa (\n Collinsella<\/jats:italic>\n ,\n Ruminococcus.AF25_28AC<\/jats:italic>\n ,\n Ruminococcus.AM42_11<\/jats:italic>\n ,\n Erysipelotrichaceae bacterium-GAM147<\/jats:italic>\n ,\n Bacteroides stercoris\/Parabacteroides merdae<\/jats:italic>\n ) correlated with reduced mortality risk. Risky taxa (\n Bacteroides.AF20_13LB<\/jats:italic>\n ,\n Veillonella.atypica<\/jats:italic>\n ,\n Veillonella.AF13_2<\/jats:italic>\n ,\n Veillonellaceae<\/jats:italic>\n and\n s_Actinomyces_sp_ICM47<\/jats:italic>\n ) showed worse OS outcomes. (4) PFS-protective taxa (\n Collinsella<\/jats:italic>\n ,\n Bacteroidales zoogleoformans<\/jats:italic>\n ,\n Ruminococcus.AF25_28AC<\/jats:italic>\n ,\n Ru-minococcus callidus<\/jats:italic>\n , and\n Erysipelotrichaceae bacterium GAM147<\/jats:italic>\n ) correlated with reduced progression risk. PFS-detrimental taxa (\n Prevotella 9<\/jats:italic>\n ,\n Bacteroides_AF20_13LB<\/jats:italic>\n ,\n Veillonella atypica<\/jats:italic>\n , and\n Lachnoclostridium<\/jats:italic>\n ) showed worse outcomes. (5) Responders showed upregulated bile acid metabolism, fatty acid biosynthesis, methanogenesis and carbon fixation pathways associated with beneficial genera, while non-responders exhibited elevated secondary bile acid metabolism, arginine biosynthesis and carbohydrate transport pathways linked to detrimental taxa.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n HCC patients with varied treatment responses exhibit characteristic shifts in gut flora. Compositional and functional variations of intestinal microbes serve as potential indicators of disease status, promising prognostic predictors, and references for clinical therapeutic decisions.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n , PROSPERO CRD420261363281.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1928103","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:26Z","timestamp":1788948746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Guo","family":"Lin","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]},{"name":"The First Clinical Medical College, Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowei","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangbin","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyi","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwu","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.jhepr.2025.101571","article-title":"Hepatocellular carcinoma: epidemiology, diagnosis and treatment","volume":"7","author":"Mauro","year":"2025","journal-title":"JHEP Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17588359251357719","DOI":"10.1177\/17588359251357719","article-title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","volume":"17","author":"Meyers","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1053\/j.gastro.2025.03.047","article-title":"Advances in locoregional and systemic treatments for hepatocellular carcinoma","volume":"169","author":"Singal","year":"2025","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e012658","DOI":"10.1136\/jitc-2025-012658","article-title":"Immune checkpoint blockade and transarterial chemoembolization in liver-limited hepatocellular carcinoma: new questions at the Dawn of a new era","volume":"13","author":"Dhyani","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e70458","DOI":"10.1002\/mco2.70458","article-title":"The gut\u2012liver axis in liver disease: molecular mechanisms and therapeutic targets","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/mmr.2024.13375","article-title":"Gut-liver axis in liver disease: from basic science to clinical treatment (review)","volume":"31","author":"Wang","year":"2024","journal-title":"Mol Med Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2486519","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/1040841X.2025.2501590","article-title":"The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma","volume":"51","author":"Yoon","year":"2025","journal-title":"Crit Rev Microbiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/JS9.0000000000003511","article-title":"The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions","volume":"112","author":"Yan","year":"2026","journal-title":"Int J Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106810","DOI":"10.4254\/wjh.v17.i7.106810","article-title":"Microbiome dysbiosis and immune checkpoint inhibitors: dual targets in hepatocellular carcinoma management","volume":"17","author":"Pamungkas","year":"2025","journal-title":"World J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis","volume":"32","author":"Shi","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/cancers16091675","article-title":"Intestinal microbiome associated with efficacy of atezolizumab and bevacizumab therapy for hepatocellular carcinoma","volume":"16","author":"Inukai","year":"2024","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.3748\/wjg.v27.i42.7340","article-title":"Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients","volume":"27","author":"Chung","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor\u2013treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/hep4.1905","article-title":"Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"6","author":"Ponziani","year":"2022","journal-title":"Hepatol Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1366131","DOI":"10.3389\/fgene.2024.1366131","article-title":"Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy","volume":"15","author":"Xin","year":"2024","journal-title":"Front Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e008686","DOI":"10.1136\/jitc-2023-008686","article-title":"Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/microorganisms14040867","article-title":"A study on the association between treatment response to atezolizumab plus bevacizumab combination therapy for advanced hepatocellular carcinoma and gut microbiota","volume":"14","author":"Tanaka","year":"2026","journal-title":"Microorganisms"},{"key":"B24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/JHC.S315696","article-title":"An exploratory study for the association of gut microbiome with efficacy of immune checkpoint inhibitor in patients with hepatocellular carcinoma","volume":"8","author":"Shen","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102370","DOI":"10.1016\/j.xcrm.2025.102370","article-title":"Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production","volume":"6","author":"Zhao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"001878","DOI":"10.1099\/jmm.0.001878","article-title":"Altered intestinal Streptococcus anginosus and 5\u03b1-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab\/bevacizumab non-responders","volume":"73","author":"Fujii","year":"2024","journal-title":"J Med Microbiol"},{"key":"B27","author":"Barcena-Varela","year":""},{"key":"B28","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.3390\/medicina61122164","article-title":"Navigating the therapeutic pathway and optimal first-line systemic therapy for hepatocellular carcinoma in the era of immune checkpoint inhibitors","volume":"61","author":"Shin","year":"2025","journal-title":"Medicina"},{"key":"B29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/cancers18010099","article-title":"Role of gut microbiome in oncogenesis and oncotherapies","volume":"18","author":"Peddireddi","year":"2026","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/life16040641","article-title":"Gut microbiota biomarkers in patients with hepatocellular carcinoma in the era of immune checkpoint inhibitors","volume":"16","author":"Cerreto","year":"2026","journal-title":"Life"},{"key":"B32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/gutjnl-2022-328403","article-title":"A longitudinal trans-kingdom gut microbial approach towards decompensation in outpatients with cirrhosis","volume":"72","author":"Bajaj","year":"2023","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1619911","DOI":"10.3389\/fgene.2025.1619911","article-title":"A metagenome-wide association study of gut microbiota in hepatitis B virus-related cirrhosis in northwest China","volume":"16","author":"Feng","year":"2025","journal-title":"Front Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41598-024-77864-y","article-title":"Key features and guidelines for the application of microbial alpha diversity metrics","volume":"15","author":"Cassol","year":"2025","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0098322","DOI":"10.1128\/spectrum.00983-22","article-title":"The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma","volume":"10","author":"Huang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101900","DOI":"10.1016\/j.xcrm.2024.101900","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13568-023-01539-6","article-title":"Identification reproducible microbiota biomarkers for the diagnosis of cirrhosis and hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"AMB Express"},{"key":"B38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13073-019-0672-4","article-title":"Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients","volume":"11","author":"Peters","year":"2019","journal-title":"Genome Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1111\/cas.15983","article-title":"Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma","volume":"114","author":"Zheng","year":"2023","journal-title":"Cancer Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1760859","DOI":"10.3389\/fmicb.2026.1760859","article-title":"Gut microbial signatures of advanced hepatocellular carcinoma and their potential diagnostic value","volume":"17","author":"Wang","year":"2026","journal-title":"Front Microbiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2283160","DOI":"10.1080\/07853890.2023.2283160","article-title":"Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasion","volume":"55","author":"Peng","year":"2023","journal-title":"Ann Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jcmgh.2023.12.003","article-title":"Antagonism between gut Ruminococcus gnavus and Akkermansia muciniphila modulates the progression of chronic hepatitis B","volume":"17","author":"Chua","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/nu17172759","article-title":"Gut dysbiosis and plasma trimethylamine oxide are associated with subclinical coronary atherosclerosis in obese patients with metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Islam","year":"2025","journal-title":"Nutrients"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.chom.2024.06.012","article-title":"Obesity-enriched gut microbe degrades myo-inositol and promotes lipid absorption","volume":"32","author":"Wu","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e00914","DOI":"10.14309\/ctg.0000000000000914","article-title":"Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma","volume":"16","author":"Che","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cells14020084","article-title":"Gut microbiome modulation in hepatocellular carcinoma: preventive role in NAFLD\/NASH progression and potential applications in immunotherapy-based strategies","volume":"14","author":"Monti","year":"2025","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/liv.15466","article-title":"Association of gut microbiome and primary liver cancer: a two-sample Mendelian randomization and case-control study","volume":"43","author":"Ma","year":"2023","journal-title":"Liver Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e3639","DOI":"10.1002\/jgm.3639","article-title":"Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism","volume":"26","author":"Lan","year":"2024","journal-title":"J Gene Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11611","DOI":"10.3390\/ijms241411611","article-title":"Gut microbiota, metabolome, and body composition signatures of response to therapy in patients with advanced melanoma","volume":"24","author":"Vandoni","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0049022","DOI":"10.1128\/msphere.00490-22","article-title":"Butyrate as a potential driver of a dysbiotic shift of the tongue microbiota","volume":"8","author":"Chen","year":"2023","journal-title":"mSphere"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1038\/s41467-020-16079-x","article-title":"Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer","volume":"11","author":"Coutzac","year":"2020","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1687901","DOI":"10.3389\/or.2025.1687901","article-title":"Gut microbiota\u2013immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities","volume":"19","author":"Yang","year":"2026","journal-title":"Oncol Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e14522","DOI":"10.1111\/1751-7915.14522","article-title":"Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK\u2013STAT signalling pathway","volume":"17","author":"Xu","year":"2024","journal-title":"Microb Biotechnol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1247614","DOI":"10.3389\/fonc.2023.1247614","article-title":"Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review","volume":"13","author":"Muscolino","year":"2023","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","volume":"11","author":"Ng","year":"2022","journal-title":"Liver Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13099-025-00761-w","article-title":"Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study","volume":"17","author":"Hashem","year":"2025","journal-title":"Gut Pathog"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1097\/TXD.0000000000001033","article-title":"Characterization of gut microbiome in liver transplant recipients with nonalcoholic steatohepatitis","volume":"6","author":"Satapathy","year":"2020","journal-title":"Transplant Direct"},{"key":"B62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2022","journal-title":"Biomolecules"},{"key":"B63","doi-asserted-by":"publisher","first-page":"E305","DOI":"10.1152\/ajpendo.00181.2020","article-title":"NOD2 In hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice","volume":"319","author":"Cavallari","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1559178","DOI":"10.3389\/fmicb.2025.1559178","article-title":"The role of intestinal microbiota and its metabolites in the occurrence and intervention of obesity","volume":"16","author":"Gao","year":"2025","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1928103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:27Z","timestamp":1788948747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1928103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":64,"alternative-id":["10.3389\/fmed.2026.1928103"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1928103","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1928103"}}